eferences 36730 Stephan, M.T., Stephan, S.B., Bak, P. et al. (2012) Synapse-directed delivery of
immunomodulators using T-cell-conjugated nanoparticles. Biomaterials,
33 (23), 5776–5787.
31 Jones, R.B., Mueller, S., Kumari, S. et al. (2017) Antigen recognition-triggered
drug delivery mediated by nanocapsule-functionalized cytotoxic T-cells.
Biomaterials, 117 , 44–53.
32 Pegram, H.J., Lee, J.C., Hayman, E.G. et al. (2012) Tumor-targeted T cells
modified to secrete IL-12 eradicate systemic tumors without need for prior
conditioning. Blood, 119 (18), 4133–4141.
33 Zhang, L., Kerkar, S.P., Yu, Z. et al. (2011) Improving adoptive T cell therapy
by targeting and controlling IL-12 expression to the tumor environment.
Mol. Ther., 19 (4), 751–759.
34 Hingtgen, S.D., Kasmieh, R., van de Water, J. et al. (2010) A novel molecule
integrating therapeutic and diagnostic activities reveals multiple aspects of stem
cell-based therapy. Stem Cells, 28 (4), 832–841.
35 Yin, J., Kim, J.-K., Moon, J.-H. et al. (2011) hMSC-mediated concurrent delivery
of endostatin and carboxylesterase to mouse xenografts suppresses glioma
initiation and recurrence. Mol. Ther., 19 (6), 1161–1169.
36 Ryu, C.H., Park, S.-H., Park, S.A. et al. (2011) Gene therapy of intracranial
glioma using interleukin 12-secreting human umbilical cord blood-derived
mesenchymal stem cells. Hum. Gene Ther., 22 (6), 733–743.
37 Leen, A.M., Rooney, C.M., and Foster, A.E. (2007) Improving T cell therapy for
cancer. Annu. Rev. Immunol., 25 (1), 243–265.
38 Robbins, P.F., Dudley, M.E., Wunderlich, J. et al. (2004) Cutting edge: persistence
of transferred lymphocyte clonotypes correlates with cancer regression in
patients receiving cell transfer therapy. J. Immunol., 173 (12), 7125–7130.
39 Chen, Y.Y., Galloway, K.E., and Smolke, C.D. (2012) Synthetic biology: advancing
biological frontiers by building synthetic systems. Genome Biol., 13 (2), 240.
40 Kalos, M. and June, C.H. (2013) Adoptive T cell transfer for cancer
immunotherapy in the era of synthetic biology. Immunity, 39 (1), 49–60.
41 Chakravarti, D. and Wong, W.W. (2015) Synthetic biology in cell-based cancer
immunotherapy. Trends Biotechnol., 33 (8), 449–461.
42 Geering, B. and Fussenegger, M. (2015) Synthetic immunology: modulating the
human immune system. Trends Biotechnol., 33 (2), 65–79.
43 Lim, W.A. and June, C.H. (2017) The principles of engineering immune cells to
treat cancer. Cell, 168 (4), 724–740.
44 Safinia, N., Leech, J., Hernandez-Fuentes, M. et al. (2013) Promoting
transplantation tolerance; adoptive regulatory T cell therapy. Clin. Exp.
Immunol., 172 (2), 158–168.
45 Bluestone, J.A. (2005) Regulatory T-cell therapy: is it ready for the clinic?
Nat. Rev. Immunol., 5 (4), 343–349.
46 Forrester, J.V., Steptoe, R.J., Klaska, I.P. et al. (2013) Cell-based therapies for
ocular inflammation. Prog. Retin. Eye Res., 35 , 82–101.
47 Li, P., Gan, Y., Sun, B.-L. et al. (2013) Adoptive regulatory T-cell therapy protects
against cerebral ischemia. Ann. Neurol., 74 (3), 458–471.
48 Schürch, C.M., Riether, C., and Ochsenbein, A.F. (2013) Dendritic cell-based
immunotherapy for myeloid leukemias. Front. Immunol., 4 , 496.